Groundbreaking technology shows immense potential for treating ischemic retinopathy

A groundbreaking technology with immense potential in treating ischemic retinopathy in premature infants and diabetic patients has been developed by Professor Byoung Heon Kang and his research team in the Department of Biological Sciences at UNIST, in collaboration with Professor Dong Ho Park’s team at Kyungpook National University Hospital. Ischemic retinopathy, characterized by the breakdown of the blood-retinal barrier and abnormal blood vessel growth, often leads to vision impairment and loss.

Pharmacological treatment reduces specific crimes in adolescents with ADHD

A study in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP), published by Elsevier, found that pharmacological treatment of attention-deficit/hyperactivity disorder

May 14, 2024

FDA explains why it denied about 60% of non-oncology breakthrough therapy requests from 2017 to 2019

The FDA is offering a look into why it denied about 60% of all breakthrough therapy designation requests it received from the biopharma industry —

November 14, 2023

Antiverse raises £3.5 M ($4.6 M) to advance generative AI antibody design platform

Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5 M ($4.6 M) to its seed funding.

October 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.